With its $67 billion market capitalization — about a third that of Pfizer or Merck — Indianapolis-based Eli Lilly often gets mentioned as a buyout candidate. But it will probably never get bought out. The reason, as Sanford C. Bernstein analyst Timothy Anderson explains in a note to investors this morning, is the state law in Indiana.
Hey, check out all the research scientist jobs. Post your resume today!
